Page 121 - Read Online

target for screening small molecules capable to interfere with 4. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL,
telomerase assembly. Indeed, for macromolecular complex, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association
the interfacial drugs have a remarkable potential application. of human telomerase activity with immortal cells and cancer. Science
1994;266:2011-5.
5. Fogarty PF, Yamaguchi H, Wiestner A, Baerlocher GM, Sloand E, Zeng
G-quadruplex stabilizers are potent ligands that indirectly WS, Read EJ, Lansdorp PM, Young NS. Late presentation of dyskeratosis
target telomerase resulting in inhibition of its activity. congenita as apparently acquired aplastic anaemia due to mutations in
BRACO-19, RHPS4 and Telomestatin are commonly telomerase RNA. Lancet 2003;362:1628-30.
studied G-quadruplex binding ligands. Recently there are 6. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C,
Lawson WE, Xie MY, Vulto I, Phillips JA 3rd, Lansdorp PM, Greider CW,
several studies showed anticancer drug candidates with Loyd JE. Telomerase mutations in families with idiopathic pulmonary
G-guadruplex as targets. [55,56] fibrosis. N Engl J Med 2007;356:1317-26.
7. Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ, Dokal I.
Immunotherapy approach which induces T lymphocytes to Mutations in dyskeratosis congenita: their impact on telomere length and
respond to hTERT antigens in malignant tumor has shown the diversity of clinical presentation. Blood 2006;107:2680-5.
good inhibitory effect. Preclinical studies with hTERT 8. Tsukuma H, Tanaka H, Ajiki W, Oshima A. Liver cancer and its prevention.
Asian Pac J Cancer Prev 2005;6:244-50.
peptides have led to successful progress in the telomerase- 9. Ding D, Lou X, Hua D, Yu W, Li L, Wang J, Gao F, Zhao N, Ren G, Li
targeting immunotherapies. Some telomerase vaccination L, Lin B. Recurrent targeted genes of hepatitis B virus in the liver cancer
such as Vx-001, GV1001 showed promising clinical outcome genomes identified by a next-generation sequencing-based approach.
for different types of tumor. [57,58] Recently an hTERT-derived PLoS Genet 2012;8:e1003065.
peptide [hTERT(461)] have shown clinical benefits in HCC 10. Collins K, Mitchell JR. Telomerase in the human organism. Oncogene
2002;21:564-79.
patients. [59] 11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
12. Carulli L, Anzivino C. Telomere and telomerase in chronic liver disease
CONCLUSION AND PERSPECTIVE and hepatocarcinoma. World J Gastroenterol 2014;20:6287-92.
13. Satyanarayana A, Manns MP, Rudolph KL. Telomeres and telomerase: a
dual role in hepatocarcinogenesis. Hepatology 2004;40:276-83.
Telomere shortening plays an important role in cell 14. Quaas A, Oldopp T, Tharun L, Klingenfeld C, Krech T, Sauter G, Grob
senescence. Telomerase which maintains the length of TJ. Frequency of TERT promoter mutations in primary tumors of the liver.
telomere connects with aging, chronic diseases as well as Virchows Arch 2014;465:673-7.
cancer promotion and progression. [17,34] By looking into 15. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH,
the telomerase gene mutations, the relation between the Aoki M, Hosono N, Kubo M, Miya F, Arai Y, Takahashi H, Shirakihara
mutants and liver disease including HCC probably is due to T, Nagasaki M, Shibuya T, Nakano K, Watanabe-Makino K, Tanaka
H, Nakamura H, Kusuda J, Ojima H, Shimada K, Okusaka T, Ueno M,
the reduced activity. Meanwhile, the mutations at noncoding Shigekawa Y, Kawakami Y, Arihiro K, Ohdan H, Gotoh K, Ishikawa O,
sequence of the telomerase also involved in the development Ariizumi S, Yamamoto M, Yamada T, Chayama K, Kosuge T, Yamaue H,
of the HCC by regulating the expression level of active Kamatani N, Miyano S, Nakagama H, Nakamura Y, Tsunoda T, Shibata
enzyme. It is commonly believed that the expression of hTERT T, Nakagawa H. Whole-genome sequencing of liver cancers identifies
may be a definitive factor in the activation of telomerase in etiological influences on mutation patterns and recurrent mutations in
chromatin regulators. Nat Genet 2012;44:760-4.
hepatocarcinogenesis, however according to the recent 16. Hartmann D, Srivastava U, Thaler M, Kleinhans KN, N’kontchou G,
[46]
paper from Xi et al. overexpression of either hTR or hTERT Scheffold A, Bauer K, Kratzer RF, Kloos N, Katz SF, Song Z, Begus-
[60]
could increase telomerase activity which indicates that the Nahrmann Y, Kleger A, von Figura G, Strnad P, Lechel A, Günes C,
two core components assemble into active telomerase is Potthoff A, Deterding K, Wedemeyer H, Ju Z, Song G, Xiao F, Gillen
an equilibrium process. Further investigation is required S, Schrezenmeier H, Mertens T, Ziol M, Friess H, Jarek M, Manns MP,
Beaugrand M, Rudolph KL. Telomerase gene mutations are associated
to elucidate the regulation of hTR gene with initiation and with cirrhosis formation. Hepatology 2011;53:1608-17.
progression of the liver cancer. 17. Buseman CM., Wright WE, Shay JW. Is telomerase a viable target in
cancer? Mutat Res 2012;730:90-7.
Financial support and sponsorship 18. Shippenlentz D, Blackburn EH. Functional evidence for an rna template in
This work was supported by the National Natural Science telomerase. Science 1990;247:546-52.
Foundation of China (Grant no. 81370088) and the Supporting 19. Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE, Bodnar
AG, Lichtsteiner S, Kim NW, Trager JB, Taylor RD, Carlos R, Andrews
Plan of Education Ministry’s New Century Excellent Talents WH, Wright WE, Shay JW, Harley CB, Morin GB. Reconstitution of
(Grant no. NCET-13-0467). human telomerase with the template RNA component hTR and the
catalytic protein subunit hTRT. Nat Genet 1997;17:498-502.
Conflicts of interest 20. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH,
There are no conflicts of interest. Lingner J, Harley CB, Cech TR. Telomerase catalytic subunit homologs
from fission yeast and human. Science 1997;277:955-9.
21. Yu RM, Chen EX, Kong RY, Ng PK, Mok HO, Au DW. Hypoxia induces
REFERENCES telomerase reverse transcriptase (TERT) gene expression in non-tumor
fish tissues in vivo: the marine medaka (Oryzias melastigma) model. BMC
1. de Lange T. Protection of mammalian telomeres. Oncogene 2002;21:532- Mol Biol 2006;7:27.
40. 22. Gillis AJ, Schuller AP, Skordalakes E. Structure of the tribolium castaneum
2. de Lange T. How telomeres solve the end-protection problem. Science telomerase catalytic subunit TERT. Nature 2008;455:633-47.
2009;326:948-52. 23. Huang J, Brown AF, Wu J, Xue J, Bley CJ, Rand DP, Wu LJ, Zhang
3. Lingner J, Cooper JP, Cech TR. Telomerase and DNA end replication - no RG, Chen JJ, Lei M. Structural basis for protein-RNA recognition in
longer a lagging-strand problem? Science 1995;269:1533-4. telomerase. Nat Struct Mol Biol 2014;21:507-12.

112 Hepatoma Research | Volume 2 | May 6, 2016